メインコンテンツにスキップ
検索

早期臨床

登録

最新のリソース

注目コンテンツ

Upcoming early clinical webinars

Latest early clinical blogs

医薬品開発におけるPK/PDモデリングのための機械学習
Machine Learning for PK/PD Modeling in Drug DevelopmentBlog

医薬品開発におけるPK/PDモデリングのための機械学習

米国FDAのモデルに基づく医薬品開発と対になったパイロットプログラムが治験依頼者を助ける方法
How the US FDA MIDD paired pilot program helps sponsorsBlog

米国FDAのモデルに基づく医薬品開発と対になったパイロットプログラムが治験依頼者を助ける方法

指標となる臨床的薬剤相互作用研究における代謝物の測定
Measuring metabolites in index clinical DDI studiesBlog

指標となる臨床的薬剤相互作用研究における代謝物の測定

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters
Why FDA’s omaveloxolone approval for Friedreich’s ataxia mattersBlog

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters

Key development considerations for cell therapies
Key development considerations for cell therapiesBlog

Key development considerations for cell therapies

医薬品開発のリスク軽減：早期開発における重要な化学、製造、および管理（CMC）および生理学的薬物動態（PBPK）アプローチ
De-risking Drug Development: Key Chemistry, Manufacturing, and Controls (CMC) and Physiologically Based Pharmacokinetic (PBPK) Approaches in Early Development Blog

医薬品開発のリスク軽減：早期開発における重要な化学、製造、および管理（CMC）および生理学的薬物動態（PBPK）アプローチ

以下のイベントで弊社のエキスパートをご紹介

展示会・学会

ACDM 2026

March 15 - 17, 2026 – Berlin, Germany – Booth 13
展示会・学会

Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development

2026年3月17日
展示会・学会

SOT Annual Meeting and ToxExpo 2026

March 22 - 25, 2026 – San Diego, CA – Booth 2024

All early clinical resources

Modeling of Pharmacokinetic Systems Using Stochastic Deconvolution

Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Publication

Differences in Cytochrome P450-mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically-based Pharmacokinetic Modeling

Model Informed Drug Development, pre-update, Publication

Absence of Pharmacokinetic Drug-drug Interaction of Pertuzumab with Trastuzumab and Docetaxel

Model Informed Drug Development, Modeling and Simulation - PK/PD, Oncology/Hematology, pre-update, Therapeutic Specialties, Publication

Introduction to Population PK/PD Analysis Using Phoenix NLME

Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, On-Demand Webinar

Predicted Heart Rate Effect of Inhaled LABA PF-00610355 in Volunteers and COPD Patients

Cardiovascular, Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Therapeutic Specialties, Publication

Effect of Meal and Antisecretory Agents on the Pharmacokinetics of Danoprevir/Ritonavir in Healthy Volunteers

Infectious Disease, Modeling and Simulation - PK/PD, pre-update, Publication

Influence of Chronic Hepatitis C Infection on Cytochrome P450 3A4 Activity Using Midazolam as an In Vivo Probe Substrate

Infectious Disease, Modeling and Simulation - PK/PD, pre-update, Publication

Inter-individual Variability in Levels of Human Microsomal Protein and Hepatocellularity per Gram of Liver

Model Informed Drug Development, pre-update, Publication

Pharmacokinetics of a Three-way Drug Interaction Between Danoprevir, Ritonavir, and the Organic Anion Transporting Polypeptide (OATP) Inhibitor Ciclosporin

Infectious Disease, Modeling and Simulation - PK/PD, pre-update, Publication

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux

Certara Products, Certara Products - Simcyp, Clinical Trials, Clinical Trials Software, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, pre-update, Publication

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin

Certara Products, Certara Products - Simcyp, Clinical Trials, Clinical Trials Software, Drug Development, Drug-Drug Interactions (DDI), Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, pre-update, Publication

Using Historical Control Information for the Design and Analysis of Clinical Trials with Overdispersed Count Data

Central Nervous System (CNS), Certara Services, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), pre-update, Therapeutic Specialties, Publication
ニュースレターを購読

今すぐ登録：医薬品開発の革新は、サターラの情熱そのものです。最新情報を入手し、ともに科学の限界を切り拓いていきましょう。


Powered by Translations.com GlobalLink Web Software